

Duncan E Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8099368/publications.pdf>

Version: 2024-02-01

10
papers

1,532
citations

933447

10
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

2947
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 533-550.	46.4	806
2	Fragment-Based Approaches in Drug Discovery and Chemical Biology. <i>Biochemistry</i> , 2012, 51, 4990-5003.	2.5	370
3	Using a Fragment-Based Approach To Target Protein-Protein Interactions. <i>ChemBioChem</i> , 2013, 14, 332-342.	2.6	115
4	Drugging challenging targets using fragment-based approaches. <i>Current Opinion in Chemical Biology</i> , 2010, 14, 299-307.	6.1	82
5	Systematic Investigation of the Permeability of Androgen Receptor PROTACs. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1539-1547.	2.8	40
6	Small-Molecule Inhibitors That Target Protein-Protein Interactions in the RAD51 Family of Recombinases. <i>ChemMedChem</i> , 2015, 10, 296-303.	3.2	36
7	A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death. <i>Cell Chemical Biology</i> , 2021, 28, 835-847.e5.	5.2	27
8	Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction. <i>FEBS Letters</i> , 2016, 590, 1094-1102.	2.8	20
9	Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase $\hat{3}$ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3359-3370.	6.4	14
10	Engineering Archeal Surrogate Systems for the Development of Protein-Protein Interaction Inhibitors against Human RAD51. <i>Journal of Molecular Biology</i> , 2016, 428, 4589-4607.	4.2	13